← Back to Clinical Trials
Recruiting NCT07134595

NCT07134595 Comparing Conventional Continuous Ambulatory Peritoneal Dialysis Prescription (C-CAPD) With Modified-CAPD (M-CAPD) Prescription in Children With End-stage Kidney Disease From Low-resource Settings

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07134595
Status Recruiting
Phase
Sponsor National University Health System, Singapore
Condition Children on Chronic Peritoneal Dialysis
Study Type INTERVENTIONAL
Enrollment 44 participants
Start Date 2024-11-18
Primary Completion 2026-06-30

Trial Parameters

Condition Children on Chronic Peritoneal Dialysis
Sponsor National University Health System, Singapore
Study Type INTERVENTIONAL
Phase N/A
Enrollment 44
Sex ALL
Min Age 2 Years
Max Age 18 Years
Start Date 2024-11-18
Completion 2026-06-30
Interventions
C-CAPD PrescriptionM-CAPD Prescription

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study aims to compare modified CAPD (M-CAPD) and conventional CAPD (C-CAPD) in terms of delivering high-quality, goal-directed PD as well as avoiding resource wastage in prevalent ESKD patients aged 2 to ≤18 years using a randomized cross-over study design for one year. This study hypothesizes that M-CAPD will have better ultrafiltration and solute clearance than C-CAPD. Specific objectives 1. To determine the ultrafiltration efficiency by measuring the following: 1. Clinical parameters: blood pressure, weight, evidence of fluid overload by the presence of edema, abnormal heart sounds (S3 gallop), lung crackles or rales, increased heart rate (tachycardia), rapid breathing (tachypnea), 2. Change in the number of blood pressure medications before and after the intervention, 3. Absolute and relative fluid overload using bioimpedance analyzer (BIA), 4. Mean daily ultrafiltration (UF) or Total 24-h UF, 5. Residual kidney function: 24-hour urine output, 6. Glucose exposure 2. To determine the solute clearance adequacy by measuring the following: 1. Serum sodium, chloride, potassium, bicarbonate, serum albumin, calcium, and hemoglobin, 2. Phosphate clearance 3. Renal and peritoneal Kt/Vurea 4. Normalized protein catabolic rate (nPCR) 3. To measure caregiver burden using a Paediatric Renal Caregiver Burden Scale (PR-CBS).

Eligibility Criteria

Inclusion Criteria: * CKD 5D who have been on peritoneal dialysis for at least three months. Exclusion Criteria: 1. Patients with BSA of ≥1.5 m2, 2. Evidence of mechanical causes of low ultrafiltration capacity (hernia, peri-catheter, or genital leaks, pleuroperitoneal communication), 3. Peritoneal membrane failure (encapsulating peritoneal sclerosis), 4. Recent episode of peritonitis (within two months) 5. Those who have been on hemodialysis before switching to PD in the last three weeks.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology